Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID J SHIH

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1134197429
CMS profile
278040
Location
NORTH DARTMOUTH, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$117.38

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $114.30 1
Education $3.08 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $114.30 1
Travere Therapeutics, Inc. $3.08 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID J SHIH

NPI 1134197429 · CMS profile ID 278040

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

NORTH DARTMOUTH, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134197429?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID J SHIH, NPI 1134197429, CMS profile ID 278040. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134197429?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DAVID J SHIH, NPI 1134197429, CMS profile ID 278040. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134197429?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DAVID J SHIH, NPI 1134197429, CMS profile ID 278040, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1134197429?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $117.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Travere Therapeutics, Inc. $3.0807/19/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149952737 CMS
AstraZeneca Pharmaceuticals LP $114.3006/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105510527 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $125.00 1
PY2020 $35.59 2
PY2022 $106.59 1
PY2023 $260.78 3
PY2024 $117.38 2
PY2025 $406.61 18

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,388,238.70 34
PY2024 Recipient $407.23 2
PY2024 Principal investigator $667,229.75 291
PY2023 Principal investigator $204,997.05 80

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

293 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bausch Health US, LLC $349.86 12/23/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675656
Principal investigator 1 Bausch Health US, LLC $3,411.94 12/11/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675665
Principal investigator 1 GlaxoSmithKline, LLC. $846.90 12/11/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1156001743
Principal investigator 1 Eli Lilly and Company $29,330.00 12/10/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1137362637
Principal investigator 1 Bausch Health US, LLC $6,565.08 12/04/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675679
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,302.92 11/27/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1110843386
Principal investigator 1 Bausch Health US, LLC $3,994.56 11/27/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675669
Principal investigator 1 GlaxoSmithKline, LLC. $400.00 11/22/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127519341
Principal investigator 1 Eli Lilly and Company $131,962.00 11/19/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY No dispute reported 06/30/2026 1137362339
Principal investigator 1 Bausch Health US, LLC $8,546.72 11/04/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675651
Principal investigator 1 Bausch Health US, LLC $2,708.44 10/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675674
Principal investigator 1 Eli Lilly and Company $1,085.01 10/20/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137362581
Principal investigator 1 Bausch Health US, LLC $5,260.01 10/09/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675660
Principal investigator 1 GlaxoSmithKline, LLC. $1,297.80 10/04/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127519413
Principal investigator 1 GlaxoSmithKline, LLC. $73.21 10/02/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127519415
Principal investigator 1 GlaxoSmithKline, LLC. $850.00 09/23/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127519337
Principal investigator 1 Bausch Health US, LLC $4,167.90 09/20/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675647
Principal investigator 1 Bausch Health US, LLC $2,320.86 09/19/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675616
Principal investigator 1 GlaxoSmithKline, LLC. $350.00 09/18/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127519343
Principal investigator 1 Eli Lilly and Company $3,235.51 09/17/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1137362341
Principal investigator 1 Bausch Health US, LLC $2,001.04 09/06/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675629
Principal investigator 1 GlaxoSmithKline, LLC. $1,007.10 09/06/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127519345
Principal investigator 1 Bausch Health US, LLC $6,979.87 08/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675621
Principal investigator 1 GlaxoSmithKline, LLC. $350.00 08/19/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127519339
Principal investigator 1 GlaxoSmithKline, LLC. $993.60 08/14/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127519419
Principal investigator 1 Bausch Health US, LLC $6,449.10 08/13/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675643
Principal investigator 1 Eli Lilly and Company $730.01 08/04/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY No dispute reported 06/30/2026 1137362639
Principal investigator 1 Bausch Health US, LLC $3,759.34 08/02/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675634
Principal investigator 1 Bausch Health US, LLC $349.86 07/31/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675625
Principal investigator 1 Bausch Health US, LLC $12,979.83 07/19/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675638
Principal investigator 1 GlaxoSmithKline, LLC. $1,957.50 07/08/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127519417
Principal investigator 1 Bausch Health US, LLC $7.66 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674895
Principal investigator 1 Bausch Health US, LLC $1,587.28 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674935
Principal investigator 1 Bausch Health US, LLC $125.00 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674949
Principal investigator 1 Bausch Health US, LLC $349.86 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674976
Principal investigator 1 Bausch Health US, LLC $26.86 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675003
Principal investigator 1 Bausch Health US, LLC $300.00 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675030
Principal investigator 1 Bausch Health US, LLC $50.00 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675042
Principal investigator 1 Bausch Health US, LLC $1,531.04 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675095
Principal investigator 1 Bausch Health US, LLC $125.00 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675100
Principal investigator 1 Bausch Health US, LLC $1,531.04 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675122
Principal investigator 1 Bausch Health US, LLC $1,587.28 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675131
Principal investigator 1 Bausch Health US, LLC $100.00 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675140
Principal investigator 1 Bausch Health US, LLC $349.86 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675144
Principal investigator 1 Bausch Health US, LLC $50.00 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675148
Principal investigator 1 Bausch Health US, LLC $50.00 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675169
Principal investigator 1 Bausch Health US, LLC $1,587.28 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675196
Principal investigator 1 Bausch Health US, LLC $349.86 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675236
Principal investigator 1 Bausch Health US, LLC $100.00 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675311
Principal investigator 1 Bausch Health US, LLC $100.00 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675347
Principal investigator 1 Bausch Health US, LLC $300.00 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675493
Principal investigator 1 Bausch Health US, LLC $18.86 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675502
Principal investigator 1 Bausch Health US, LLC $349.86 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675519
Principal investigator 1 Bausch Health US, LLC $100.00 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675581
Principal investigator 1 Bausch Health US, LLC $3.36 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675585
Principal investigator 1 Bausch Health US, LLC $1,587.28 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675594
Principal investigator 1 Bausch Health US, LLC $50.00 06/26/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675598
Principal investigator 1 Eli Lilly and Company $89,127.00 06/18/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137361469
Principal investigator 1 GlaxoSmithKline, LLC. $3,011.40 06/14/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127519411
Principal investigator 1 Bausch Health US, LLC $50.00 06/13/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674980
Principal investigator 1 Bausch Health US, LLC $100.00 06/13/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675091
Principal investigator 1 Bausch Health US, LLC $100.00 06/13/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675302
Principal investigator 1 Bausch Health US, LLC $100.00 06/13/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675333
Principal investigator 1 Bausch Health US, LLC $43.94 06/13/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675360
Principal investigator 1 Bausch Health US, LLC $49.91 06/13/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675364
Principal investigator 1 Bausch Health US, LLC $50.00 06/13/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675395
Principal investigator 1 Bausch Health US, LLC $38.68 06/13/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675448
Principal investigator 1 Bausch Health US, LLC $5.42 06/13/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675510
Principal investigator 1 Bausch Health US, LLC $50.00 06/13/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675576
Principal investigator 1 Eli Lilly and Company $141,578.00 06/11/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137361957
Principal investigator 1 Bausch Health US, LLC $50.00 06/05/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675055
Principal investigator 1 Bausch Health US, LLC $22.93 06/05/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675209
Principal investigator 1 Bausch Health US, LLC $349.86 06/05/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675227
Principal investigator 1 Bausch Health US, LLC $100.00 06/05/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675245
Principal investigator 1 Bausch Health US, LLC $150.00 06/05/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675267
Principal investigator 1 Bausch Health US, LLC $349.86 06/05/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675284
Principal investigator 1 Bausch Health US, LLC $5.42 06/05/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675329
Principal investigator 1 Bausch Health US, LLC $5.42 06/05/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675342
Principal investigator 1 Bausch Health US, LLC $349.86 06/05/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675355
Principal investigator 1 Bausch Health US, LLC $349.86 06/05/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675387
Principal investigator 1 Bausch Health US, LLC $38.68 06/05/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675453
Principal investigator 1 Bausch Health US, LLC $7.66 06/05/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675484
Principal investigator 1 Bausch Health US, LLC $1,651.18 06/05/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675497
Principal investigator 1 Bausch Health US, LLC $150.00 06/05/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675537
Principal investigator 1 Bausch Health US, LLC $1,531.04 06/05/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675554
Principal investigator 1 Bausch Health US, LLC $38.76 06/05/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675607
Principal investigator 1 Bausch Health US, LLC $349.86 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674860
Principal investigator 1 Bausch Health US, LLC $79.05 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674878
Principal investigator 1 Bausch Health US, LLC $1,587.28 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674882
Principal investigator 1 Bausch Health US, LLC $100.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674904
Principal investigator 1 Bausch Health US, LLC $100.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674909
Principal investigator 1 Bausch Health US, LLC $26.86 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674913
Principal investigator 1 Bausch Health US, LLC $50.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674922
Principal investigator 1 Bausch Health US, LLC $1,200.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674931
Principal investigator 1 Bausch Health US, LLC $1,587.28 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674944
Principal investigator 1 Bausch Health US, LLC $349.86 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674953
Principal investigator 1 Bausch Health US, LLC $349.86 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674963
Principal investigator 1 Bausch Health US, LLC $1,531.04 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674967
Principal investigator 1 Bausch Health US, LLC $100.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674971
Principal investigator 1 Bausch Health US, LLC $50.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674985
Principal investigator 1 Bausch Health US, LLC $1,531.04 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674994
Principal investigator 1 Bausch Health US, LLC $1,651.18 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674998
Principal investigator 1 Bausch Health US, LLC $349.86 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675016
Principal investigator 1 Bausch Health US, LLC $1,651.18 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675020
Principal investigator 1 Bausch Health US, LLC $1,587.28 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675025
Principal investigator 1 Bausch Health US, LLC $349.86 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675038
Principal investigator 1 Bausch Health US, LLC $100.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675060
Principal investigator 1 Bausch Health US, LLC $50.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675064
Principal investigator 1 Bausch Health US, LLC $125.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675069
Principal investigator 1 Bausch Health US, LLC $1,531.04 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675082
Principal investigator 1 Bausch Health US, LLC $50.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675105
Principal investigator 1 Bausch Health US, LLC $45.86 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675113
Principal investigator 1 Bausch Health US, LLC $50.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675118
Principal investigator 1 Bausch Health US, LLC $125.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675127
Principal investigator 1 Bausch Health US, LLC $1,587.28 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675157
Principal investigator 1 Bausch Health US, LLC $349.86 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675173
Principal investigator 1 Bausch Health US, LLC $1,587.28 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675178
Principal investigator 1 Bausch Health US, LLC $100.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675187
Principal investigator 1 Bausch Health US, LLC $50.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675191
Principal investigator 1 Bausch Health US, LLC $50.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675205
Principal investigator 1 Bausch Health US, LLC $50.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675218
Principal investigator 1 Bausch Health US, LLC $36.68 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675222
Principal investigator 1 Bausch Health US, LLC $100.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675240
Principal investigator 1 Bausch Health US, LLC $20.54 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675262
Principal investigator 1 Bausch Health US, LLC $300.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675280
Principal investigator 1 Bausch Health US, LLC $1,531.04 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675288
Principal investigator 1 Bausch Health US, LLC $300.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675306
Principal investigator 1 Bausch Health US, LLC $5.42 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675324
Principal investigator 1 Bausch Health US, LLC $1,651.18 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675338
Principal investigator 1 Bausch Health US, LLC $1,531.04 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675351
Principal investigator 1 Bausch Health US, LLC $35.50 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675369
Principal investigator 1 Bausch Health US, LLC $100.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675382
Principal investigator 1 Bausch Health US, LLC $1,531.04 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675391
Principal investigator 1 Bausch Health US, LLC $18.86 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675400
Principal investigator 1 Bausch Health US, LLC $30.78 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675404
Principal investigator 1 Bausch Health US, LLC $7.66 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675413
Principal investigator 1 Bausch Health US, LLC $100.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675417
Principal investigator 1 Bausch Health US, LLC $100.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675421
Principal investigator 1 Bausch Health US, LLC $349.86 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675457
Principal investigator 1 Bausch Health US, LLC $18.18 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675462
Principal investigator 1 Bausch Health US, LLC $50.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675479
Principal investigator 1 Bausch Health US, LLC $50.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675506
Principal investigator 1 Bausch Health US, LLC $100.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675515
Principal investigator 1 Bausch Health US, LLC $50.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675528
Principal investigator 1 Bausch Health US, LLC $100.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675532
Principal investigator 1 Bausch Health US, LLC $1,531.04 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675541
Principal investigator 1 Bausch Health US, LLC $100.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675559
Principal investigator 1 Bausch Health US, LLC $36.88 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675572
Principal investigator 1 Bausch Health US, LLC $50.00 05/16/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675603
Principal investigator 1 Bausch Health US, LLC $2,853.77 05/14/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675051
Principal investigator 1 Bausch Health US, LLC $1,281.83 05/14/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675078
Principal investigator 1 Bausch Health US, LLC $1,281.83 05/14/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675161
Principal investigator 1 Bausch Health US, LLC $1,281.83 05/14/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675378
Principal investigator 1 Bausch Health US, LLC $2,138.09 05/10/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674900
Principal investigator 1 Bausch Health US, LLC $1,587.28 05/10/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674918
Principal investigator 1 Bausch Health US, LLC $349.86 05/10/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674958
Principal investigator 1 Bausch Health US, LLC $1,587.28 05/10/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674989
Principal investigator 1 Bausch Health US, LLC $2,138.09 05/10/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675034
Principal investigator 1 Bausch Health US, LLC $1,695.91 05/10/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675135
Principal investigator 1 Bausch Health US, LLC $1,574.50 05/10/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675153
Principal investigator 1 Bausch Health US, LLC $1,594.94 05/10/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675201
Principal investigator 1 Bausch Health US, LLC $1,695.91 05/10/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675249
Principal investigator 1 Bausch Health US, LLC $2,138.09 05/10/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675258
Principal investigator 1 Bausch Health US, LLC $349.86 05/10/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675320
Principal investigator 1 Bausch Health US, LLC $1,531.04 05/10/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675373
Principal investigator 1 Bausch Health US, LLC $1,695.91 05/10/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675435
Principal investigator 1 Bausch Health US, LLC $2,138.09 05/10/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675488
Principal investigator 1 Eli Lilly and Company $2,068.37 05/08/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137361959
Principal investigator 1 GlaxoSmithKline, LLC. $22,660.00 05/03/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127519421
Principal investigator 1 Eli Lilly and Company $8,715.71 04/30/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137362583
Recipient Eli Lilly and Company $220.81 04/24/2024 Covered Recipient Physician A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137346646
Principal investigator 1 Bausch Health US, LLC $100.00 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674865
Principal investigator 1 Bausch Health US, LLC $100.00 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674869
Principal investigator 1 Bausch Health US, LLC $100.00 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674873
Principal investigator 1 Bausch Health US, LLC $50.00 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674887
Principal investigator 1 Bausch Health US, LLC $50.00 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674891
Principal investigator 1 Bausch Health US, LLC $30.78 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674940
Principal investigator 1 Bausch Health US, LLC $100.00 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675007
Principal investigator 1 Bausch Health US, LLC $36.88 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675047
Principal investigator 1 Bausch Health US, LLC $5.42 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675073
Principal investigator 1 Bausch Health US, LLC $1,587.28 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675109
Principal investigator 1 Bausch Health US, LLC $50.00 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675165
Principal investigator 1 Bausch Health US, LLC $18.18 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675182
Principal investigator 1 Bausch Health US, LLC $100.00 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675231
Principal investigator 1 Bausch Health US, LLC $100.00 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675253
Principal investigator 1 Bausch Health US, LLC $50.00 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675271
Principal investigator 1 Bausch Health US, LLC $29.42 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675297
Principal investigator 1 Bausch Health US, LLC $26.87 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675426
Principal investigator 1 Bausch Health US, LLC $37.85 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675439
Principal investigator 1 Bausch Health US, LLC $50.00 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675444
Principal investigator 1 Bausch Health US, LLC $3.36 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675466
Principal investigator 1 Bausch Health US, LLC $1,531.04 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675524
Principal investigator 1 Bausch Health US, LLC $50.00 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675590
Principal investigator 1 Bausch Health US, LLC $1,587.28 04/12/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675612
Principal investigator 1 Bausch Health US, LLC $1,594.94 04/02/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151674926
Principal investigator 1 Bausch Health US, LLC $1,587.28 04/02/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675011
Principal investigator 1 Bausch Health US, LLC $349.86 04/02/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675087
Principal investigator 1 Bausch Health US, LLC $1,695.91 04/02/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675214
Principal investigator 1 Bausch Health US, LLC $1,531.04 04/02/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675275
Principal investigator 1 Bausch Health US, LLC $1,594.94 04/02/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675293
Principal investigator 1 Bausch Health US, LLC $349.86 04/02/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675315
Principal investigator 1 Bausch Health US, LLC $1,594.94 04/02/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675408
Principal investigator 1 Bausch Health US, LLC $349.86 04/02/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675430
Principal investigator 1 Bausch Health US, LLC $1,531.04 04/02/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675470
Principal investigator 1 Bausch Health US, LLC $1,594.94 04/02/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675475
Principal investigator 1 Bausch Health US, LLC $349.86 04/02/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675545
Principal investigator 1 Bausch Health US, LLC $1,594.94 04/02/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675550
Principal investigator 1 Bausch Health US, LLC $1,531.04 04/02/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675563
Principal investigator 1 Bausch Health US, LLC $1,587.28 04/02/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675567
Principal investigator 1 Bausch Health US, LLC $1,587.28 03/15/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675700
Principal investigator 1 Bausch Health US, LLC $1,594.94 03/15/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675724
Principal investigator 1 Bausch Health US, LLC $2,138.09 03/15/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675751
Principal investigator 1 Bausch Health US, LLC $1,695.91 03/15/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675891
Principal investigator 1 Bausch Health US, LLC $1,695.91 03/15/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675909
Principal investigator 1 Bausch Health US, LLC $1,695.91 03/15/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675953
Principal investigator 1 Bausch Health US, LLC $349.86 03/15/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675962
Principal investigator 1 Bausch Health US, LLC $1,531.04 03/15/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675992
Principal investigator 1 Bausch Health US, LLC $1,587.28 03/15/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151676014
Principal investigator 1 Bausch Health US, LLC $1,281.83 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675696
Principal investigator 1 Bausch Health US, LLC $100.00 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675733
Principal investigator 1 Bausch Health US, LLC $50.00 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675742
Principal investigator 1 Bausch Health US, LLC $100.00 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675791
Principal investigator 1 Bausch Health US, LLC $26.86 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675800
Principal investigator 1 Bausch Health US, LLC $26.86 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675808
Principal investigator 1 Bausch Health US, LLC $20.54 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675813
Principal investigator 1 Bausch Health US, LLC $50.00 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675822
Principal investigator 1 Bausch Health US, LLC $100.00 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675826
Principal investigator 1 Bausch Health US, LLC $38.68 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675831
Principal investigator 1 Bausch Health US, LLC $100.00 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675853
Principal investigator 1 Bausch Health US, LLC $50.00 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675884
Principal investigator 1 Bausch Health US, LLC $50.00 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675900
Principal investigator 1 Bausch Health US, LLC $50.00 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675905
Principal investigator 1 Bausch Health US, LLC $50.00 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675918
Principal investigator 1 Bausch Health US, LLC $100.00 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675940
Principal investigator 1 Bausch Health US, LLC $100.00 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675948
Principal investigator 1 Bausch Health US, LLC $100.00 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675970
Principal investigator 1 Bausch Health US, LLC $100.00 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151676001
Principal investigator 1 Bausch Health US, LLC $50.00 02/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151676031
Principal investigator 1 Bausch Health US, LLC $50.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675683
Principal investigator 1 Bausch Health US, LLC $50.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675687
Principal investigator 1 Bausch Health US, LLC $50.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675706
Principal investigator 1 Bausch Health US, LLC $33.48 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675737
Principal investigator 1 Bausch Health US, LLC $100.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675746
Principal investigator 1 Bausch Health US, LLC $100.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675768
Principal investigator 1 Bausch Health US, LLC $50.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675777
Principal investigator 1 Bausch Health US, LLC $100.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675782
Principal investigator 1 Bausch Health US, LLC $100.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675786
Principal investigator 1 Bausch Health US, LLC $50.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675795
Principal investigator 1 Bausch Health US, LLC $100.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675804
Principal investigator 1 Bausch Health US, LLC $36.88 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675817
Principal investigator 1 Bausch Health US, LLC $100.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675839
Principal investigator 1 Bausch Health US, LLC $2,375.66 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675844
Principal investigator 1 Bausch Health US, LLC $50.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675848
Principal investigator 1 Bausch Health US, LLC $5.42 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675857
Principal investigator 1 Bausch Health US, LLC $20.54 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675862
Principal investigator 1 Bausch Health US, LLC $50.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675866
Principal investigator 1 Bausch Health US, LLC $26.86 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675871
Principal investigator 1 Bausch Health US, LLC $100.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675875
Principal investigator 1 Bausch Health US, LLC $100.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675879
Principal investigator 1 Bausch Health US, LLC $150.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675888
Principal investigator 1 Bausch Health US, LLC $100.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675896
Principal investigator 1 Bausch Health US, LLC $50.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675914
Principal investigator 1 Bausch Health US, LLC $34.51 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675922
Principal investigator 1 Bausch Health US, LLC $3.36 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675927
Principal investigator 1 Bausch Health US, LLC $150.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675931
Principal investigator 1 Bausch Health US, LLC $50.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675935
Principal investigator 1 Bausch Health US, LLC $50.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675944
Principal investigator 1 Bausch Health US, LLC $38.68 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675957
Principal investigator 1 Bausch Health US, LLC $50.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675966
Principal investigator 1 Bausch Health US, LLC $30.78 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675975
Principal investigator 1 Bausch Health US, LLC $7.66 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675997
Principal investigator 1 Bausch Health US, LLC $33.48 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151676005
Principal investigator 1 Bausch Health US, LLC $100.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151676009
Principal investigator 1 Bausch Health US, LLC $18.18 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151676022
Principal investigator 1 Bausch Health US, LLC $100.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151676027
Principal investigator 1 Bausch Health US, LLC $20.54 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151676035
Principal investigator 1 Bausch Health US, LLC $100.00 02/22/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151676040
Recipient Eli Lilly and Company $186.42 02/05/2024 Covered Recipient Physician A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137346648
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,252.10 01/29/2024 Non-covered Recipient Entity
LUCIDA CLINICAL TRIALS
A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease No dispute reported 06/30/2026 1110843248
Principal investigator 1 Bausch Health US, LLC $125.00 01/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675755
Principal investigator 1 Bausch Health US, LLC $300.00 01/29/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151676018
Principal investigator 1 Bausch Health US, LLC $50.00 01/19/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675691
Principal investigator 1 Bausch Health US, LLC $3.36 01/19/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675711
Principal investigator 1 Bausch Health US, LLC $100.00 01/19/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675715
Principal investigator 1 Bausch Health US, LLC $30.78 01/19/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675719
Principal investigator 1 Bausch Health US, LLC $50.00 01/19/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675728
Principal investigator 1 Bausch Health US, LLC $18.86 01/19/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675759
Principal investigator 1 Bausch Health US, LLC $100.00 01/19/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675764
Principal investigator 1 Bausch Health US, LLC $50.00 01/19/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675773
Principal investigator 1 Bausch Health US, LLC $95.61 01/19/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675835
Principal investigator 1 Bausch Health US, LLC $50.00 01/19/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675979
Principal investigator 1 Bausch Health US, LLC $100.00 01/19/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675984
Principal investigator 1 Bausch Health US, LLC $100.00 01/19/2024 Non-covered Recipient Entity
Lucida Clinicial Trials LLC
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151675988